ESMO26: MSD and Moderna drop cancer vaccine trial data early
MSD and Moderna have reported full Phase III results for their personalised cancer vaccine, but both companies’ shares fell after…
Latest News
-
-
AbbVie’s skin disease drug posts Phase III win as market competition heats up
AbbVie’s hidradenitis suppurativa (HS) candidate lutikizumab has demonstrated its potential to significantly reduce flares of the disease, though a the…
-
Roivant eyes Lisraya label expansion on Phase III uveitis win
Roivant and its subsidiary, Priovant Therapeutics, have scored another late-stage win for their marketed ophthalmology therapy, Lisraya (brepocitinib), in non-infectious…
-
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Sanofi and Teva Pharmaceuticals’ inflammatory bowel disease (IBD) drug has shown benefit in patients with both ulcerative colitis (UC) and…
-
Rapport’s novel oral drug posts Phase II bipolar win
Rapport Therapeutics’ Phase II bipolar mania study has met its primary endpoint, as it hopes to compete on the market…
-
EyePoint halves workforce and ends Phase III trial early after endpoint miss
EyePoint Pharmaceuticals has announced sweeping job cuts after its eye disease candidate, duravyu, failed to meet its key goal during…
-
Veradermics’ stock up on male hair loss trial success
Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair loss drug…
-
Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC
Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown a 50% clinical remission rate in paediatric patients with ulcerative colitis (UC). In the…
-
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a…
-
BioNTech misses PFS endpoints in Phase II/III cancer vaccine trial
One of BioNTech's prospective cancer vaccines has failed to show benefit in one of its dual primary endpoints in a…
